{'fraction_non_alphanumeric': 0.029535864978902954, 'fraction_numerical': 0.008438818565400843, 'mean_word_length': 4.648809523809524, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prospects of TIM-3 as a Promising Diagnostic and Prognostic Biomarker for Cancer Patients.

T cell immunoglobulin mucin-3 (TIM-3) is expressed on the surface of most immune cells and is involved in anti-tumor immunity. In recent years, diagnoses and therapies based on the TIM-3 target have advanced substantially in clinical trials. In this review, we summarized the progress of TIM-3 as a biomarker in the field of diagnosis and prognosis of cancer. In the peripheral blood of cancer patients, the expression level of TIM-3 on T cells is significantly higher than that of control samples, which can be a physiological indicator of cancer. Moreover, in the cancer tissue of patients, the high expression level of TIM-3 on tumor-infiltrating T cells is negatively correlated with relapse-free survival time, which can act as a promising prognostic marker. In conclusion, the TIM-3 is a promising biomarker for the diagnosis and prognosis of cancer.